PET/CT boosts classification of incidental adrenal masses

Article

In what is possibly the largest study of its kind, Harvard University researchers have shown that PET/CT can reliably tell whether unsuspected adrenal lesions discovered while managing oncologic patients are benign or malignant.

In what is possibly the largest study of its kind, Harvard University researchers have shown that PET/CT can reliably tell whether unsuspected adrenal lesions discovered while managing oncologic patients are benign or malignant.

Incidental adrenal lesions in patients with cancer require accurate characterization because their status can significantly affect staging, therapy, and prognosis. Several imaging tests are available to offer a helping hand, including contrast/noncontrast CT and MRI. None, however, has proven conclusive.

A 2006 Massachusetts General Hospital study of 38 patients found PET/CT to be sensitive and specific for the characterization of incidental adrenal lesions (Blake MA, Slattery JM, Kalra MK. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy-initial experience. Radiology 2006;238(3):970-977). The results encouraged an investigative group led by Dr. Giles W. L. Boland, an associate professor of radiology at Mass General, to validate the findings in a larger cohort of patients.

Between October 2004 and March 2007, Boland and colleagues evaluated 150 patients with various malignancies, including lymphoma and lung, head and neck, and colorectal cancer. All patients underwent noncontrast PET/CT and a follow-up CT scan six months later. The researchers confirmed that PET/CT was highly effective for differentiating benign from malignant adrenal disease in this patient population. Based on a qualitative analysis, PET/CT yielded sensitivity, specificity, accuracy, and positive and negative predictive values for characterization of benign adrenal "incidentalomas" of 100%, 97%, 98%, 87%, and 100%, respectively.

Boland cautioned the study had several limitations, including the retrospective nature of the sample. He called for careful consideration of many other criteria, including the Hounsfield unit and standardized uptake value measurements, adrenal wash-outs, and lesion size assessments. But the findings showed a way forward, he said.

"PET/CT is indeed an accurate test," Boland said.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.